Allergy Clinical Trial
— AsthmaVentOfficial title:
AsthmaVent - Effect of Mechanical Ventilation on Asthma Control in Children
Verified date | May 2016 |
Source | University of Aarhus |
Contact | n/a |
Is FDA regulated | No |
Health authority | Denmark: Danish Dataprotection Agency |
Study type | Interventional |
AsthmaVent is a multi-center study, investigating the association between indoor air quality
and childhood asthma.
In Denmark, we spend more and more time indoors. Our houses are built airtight to save
energy and are difficult to ventilate. We are thus more exposed to our indoor air than ever
before. We know that indoor air contains many different components that can affect our
airways inappropriately and particularly children with asthma, who have sensitive airways
are sensitive to these components. The AsthmaVent project examines whether increased
ventilation is able to improve the indoor environment to such an extent that the asthma
disease control, for children with asthma and house dust mite allergy improves, resulting in
need for less medication.
Previous studies have pointed towards a beneficial effect of mechanical ventilation, on both
the indoor air quality and on children's health and quality of life. There is not currently
a consensus in this area, as studies so far have not been large or good enough to
confidently determine the effect.
This project is big and is designed so that it takes into account the sources of error seen
in previous studies on the topic.
We include, over a 3-year period (2012-2014), a total of 80 children with asthma and house
dust mite allergy aged 6-18 years, from pediatric departments in Aarhus, Odense, Kolding,
Randers and Herning. They are divided into two groups, receiving either active ventilation
or placebo ventilation, meaning a non-functioning ventilation system that just recirculates
the air in the room. Ventilation systems are installed in the fall and winter and ventilate
the child's bedroom during 9 months. Indoor air quality and asthma control are assessed
every 3 months, both at home visits were air quality and allergen levels of house dust mites
are studies and at visits to the outpatient clinics with control of asthma parameters and
quality of life.
The project involves collaboration between several institutions with an interest in indoor
air quality in relation to allergies and asthma and with great expertise in the field.The
project was initiated by CISBO (Centre for Indoor Environment and Health in Dwellings), a
center consisting of several institutions in Denmark dealing with indoor environment:
Department of Public Health at Aarhus University and University of Copenhagen, Danish
Building Research Institute and the Technical University of Denmark.
Since asthma is the most common chronic childhood disease in Denmark and since the
development of allergies and asthma has high social and personal costs, it is important for
both society and the individual family, to find out whether simply improving the indoor air
quality by increased ventilation can lead to an improvement in asthma disease control.
Status | Completed |
Enrollment | 46 |
Est. completion date | February 2016 |
Est. primary completion date | February 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 5 Years to 18 Years |
Eligibility |
Inclusion Criteria: - Doctors diagnosed asthma - Need of inhaled steroid titrated down to at least 400 microg/day of Budesonide or equivalent dose of other corticosteroid - Skin prick test >/= 3 mm or specific IgE >/= 0,7 kU/l to house dust mites (Derm. Pteronyssinus and/or Derm. Farinae) - more than 500 nanog/gr dust of house dust mite allergen in the childs mattress. - Living in a one-family house and will allow changes of the house during the intervention period. - Capable of giving informed consent. Exclusion Criteria: - Other clinically relevant allergies to tree pollen or animals present in the house. - Other diseases or treatments, as for example immunotherapy, which could influence the results. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Denmark | Childrens Department, Aarhus University Hospital | Aarhus | Region Midt |
Denmark | Børneafdelingen Herlev Hospital | Herlev | Region Hovedstaden |
Denmark | Childrens Department, Herning Hospital | Herning | Region Midt |
Denmark | Childrens Department, Hillerød hospital | Hillerød | Region Nordsjælland |
Denmark | Childrens Department, Kolding Hospital | Kolding | Region Syddanmark |
Denmark | H.C. Andersens Children Hospital, Odense University Hospital | Odense | Region Syddanmark |
Denmark | Childrens DEpartment, Randers Hospital | Randers | Region Midt |
Lead Sponsor | Collaborator |
---|---|
University of Aarhus |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in dose of inhaled corticosteroid | Measured in micrograms of a specific inhaled corticosteroid | Baseline, 3 months, 6 months and 9 months | No |
Primary | Changes in particle concentration in child bedroom | Measured as particles pr. m3 | baseline, 3 months, 6 months and 9 months | No |
Secondary | FEV1 | Forced Expiratory Volume after 1 second | Baseline, 3,6 and 9 months | No |
Secondary | FeNO | Forced Expiratory Nitric Oxide | Baseline, 3,6 and 9 months | No |
Secondary | Quality of Life | Pediatric Asthma Quality of Life Questionaire | Baseline, 3,6 and 9 months | No |
Secondary | Standard Skin-prick-test and Specific IgE- phadiatop | Reduction in diameter of skin-prick-test for standard inhalant allergens and reduction in specific IgE for standard inhalant allergens measured in kU/l. | Baseline and 9 months | No |
Secondary | Asthma Symptoms | Assessed from a Symptom score scheme | During 14 days at baseline, 3, 6 and 9 months | No |
Secondary | Peakflow variability | Baseline, 3, 6 and 9 months | No | |
Secondary | Ventilation rate | Ventilation rate in the childs bedroom and in the Whole house | Baseline, 3, 6 and 9 months | No |
Secondary | Physical conditions in the child bedroom and whole house | Changes in temperature and humidity | baseline, 3 6 and 9 months | No |
Secondary | Allergens in child mattress and airborne in child bedroom | Reduction in allergen levels. | baseline, 3, 6 and 9 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02032056 -
Effect of Probiotics in Reducing Infections and Allergies in Young Children During the Complementary Feeding Period
|
N/A | |
Completed |
NCT01842711 -
Cumulative Irritation Patch Test
|
N/A | |
Completed |
NCT01633840 -
New Validated Recipes for Double-blind Placebo-controlled Low Dose Food Challenges
|
N/A | |
Completed |
NCT00554983 -
Efficacy and Safety From a Recombinant Folding Variant of Bet v 1
|
Phase 3 | |
Completed |
NCT00997971 -
Growth, Tolerance in Healthy Infants Fed a Partially Hydrolyzed Rice Protein
|
Phase 3 | |
Completed |
NCT00331929 -
Respiratory Health Study of Children in Kiryat Tivon
|
N/A | |
Completed |
NCT00220753 -
Air Cleaners for Children and Adolescents With Asthma and Dog Allergy
|
N/A | |
Completed |
NCT00232518 -
Randomised Controlled Clinical Trials of the Effect of Therapeutic Hookworm Infection in Allergic Rhinoconjunctivitis
|
N/A | |
Completed |
NCT04046731 -
Neuromuscular Blocking Agents Utilized During Perioperative Hypersensitivity Evaluation
|
N/A | |
Completed |
NCT04126096 -
Negative Predictive Value and NIC of Beta-Lactam Antibiotics.
|
N/A | |
Completed |
NCT04004351 -
Treatment Modalities in Children and Adolescents Suffering From HDM-induced Allergic Rhinitis and/or Asthma
|
||
Not yet recruiting |
NCT05997784 -
Study of Indoor Air Pollutants and Their Impact in Childhood Health and Wellbeing
|
||
Completed |
NCT04418999 -
Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus
|
Early Phase 1 | |
Completed |
NCT04186949 -
Early Origins of Allergy and Asthma
|
||
Completed |
NCT02127801 -
Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Participants
|
Phase 1 | |
Enrolling by invitation |
NCT05011071 -
The Alberta BLOOM Premature Child Study
|
||
Not yet recruiting |
NCT06330974 -
Allergy, Asthma, and Atopic Eczema in Finland
|
||
Completed |
NCT02306473 -
The Leaky Lung Test
|
Early Phase 1 | |
Completed |
NCT02596321 -
A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With HDM-Induced Allergic Rhinitis and/or Atopic Asthma
|
Phase 3 | |
Terminated |
NCT02601690 -
Observational Analysis of T Cell Responses to SPIREs for Multiple Allergens in Subjects With Allergy in North America
|